அழற்சி குடல் நோய்கள் மற்றும் கோளாறுகளின் இதழ்

Paradoxical cases of psoriatic lesions induced or exacerbated by anti-tumor necrosis factor (TNF)-α therapy have been reported more frequently in recent years, but data related to inflammatory bowel disease (IBD) are rare. A systematic literature review was performed to provide information about this adverse effect in patients with IBD who receive anti-TNF therapy. Paradoxical cases of psoriatic lesions induced or exacerbated by anti-tumor necrosis factor (TNF)-α therapy have been reported more frequently in recent years, but data related to inflammatory bowel disease (IBD) are rare. A systematic literature review was performed to provide information about this adverse effect in patients with IBD who receive anti- TNF therapy. In the last few years, tumor necrosis factor-alpha (TNF-α) antagonists such as infliximab and adalimumab have revolutionized the treatment of inflammatory bowel disease (IBD) and psoriasis.2However, as the use of these biologic agents has increased, reactivation of latent infections, cutaneous reactions (eczematous, neoplastic, granulomatous, and psoriatic lesions), and other side effects have been documented.

Confusing instances of psoriatic sores prompted or exacerbated by hostile to cancer corruption factor (TNF)- α treatment have been accounted for additional regularly lately, yet information connected with provocative inside infection (IBD) are interesting. A precise writing survey was performed to give data about this unfavorable impact in patients with IBD who get hostile to TNF treatment. Dumbfounding instances of psoriatic sores actuated or exacerbated by against growth rot factor (TNF)- α treatment have been accounted for additional habitually lately, however information connected with incendiary entrail sickness (IBD) are uncommon. An orderly writing survey was performed to give data about this unfriendly impact in patients with IBD who get hostile to TNF treatment. Over the most recent couple of years, growth corruption factor-alpha (TNF-α) adversaries like infliximab and adalimumab have upset the treatment of incendiary entrail illness (IBD) and psoriasis.2However, as the utilization of these biologic specialists has expanded, reactivation of inactive infections,3 cutaneous responses (eczematous, neoplastic, granulomatous, and psoriatic sores), and opposite secondary effects have been archived.